

- (51) International Patent Classification:
Not classified
- (21) International Application Number:
PCT/EP2024/060657
- (22) International Filing Date:
19 April 2024 (19.04.2024)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
23315089.5 20 April 2023 (20.04.2023) EP
- (71) Applicant: **LES LABORATOIRES SERVIER** [FR/FR];
35 rue de Verdun, 92284 SURESNES Cedex (FR).
- (72) Inventors: **MAHIEUX, Julien**; Technologie Servier, 27,
rue Eugène Vignat, 45000 Orléans (FR). **VILLARD, Frédéric**; Technologie Servier, 27, rue Eugène Vignat,
45000 Orléans (FR).

(74) Agent: **GIUDICELLI, Cathy**; 35, rue de Verdun, 92284 SURESNES Cedex (FR).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:
— without international search report and to be republished upon receipt of that report (Rule 48.2(g))

(54) Title: NOVEL TRIMETAZIDINE SOLID PHASES

(57) Abstract: The present invention relates to novel trimetazidine solid phases, leading to a reduced formation of trimetazidine nitrosamine in presence of nitrites.